Abstract:B cells are fundamental players in the pathophysiology of autoimmune diseases of the central nervous system, such as multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). A deeper understanding of disease-specific B cell functions has led to the differentiation of both diseases and the development of different treatment strategies. While NMOSD is strongly associated with pathogenic anti-AQP4 IgG antibodies and proinflammatory cytokine pathways, no valid autoantibodies have been identified in MS yet, apart from certain antigen targets that require further evaluation. Although both diseases can be effectively treated with B cell depleting therapies, there are distinct differences in the peripheral B cell subsets that influence CNS inflammation. An increased peripheral blood double negative B cells (DN B cells) and plasmablast populations has been demonstrated in NMOSD, but not consistently in MS patients. Furthermore, DN B cells are also elevated in rheumatic diseases and other autoimmune entities such as myasthenia gravis and Guillain-Barré syndrome, providing indirect evidence for a possible involvement of DN B cells in other autoantibody-mediated diseases. In MS, the peripheral memory B cell pool is affected by many treatments, providing indirect evidence for the involvement of memory B cells in MS pathophysiology. Moreover, it must be considered that an important effector function of B cells in MS may be the presentation of antigens to peripheral immune cells, including T cells, since B cells have been shown to be able to recirculate in the periphery after encountering CNS antigens. In conclusion, there are clear differences in the composition of B cell populations in MS and NMOSD and treatment strategies differ, with the exception of broad B cell depletion. This review provides a detailed overview of the role of different B cell subsets in MS and NMOSD and their implications for treatment options. Specifically targeting DN B cells and plasmablasts in NMOSD as opposed to memory B cells in MS may result in more precise B cell therapies for both diseases.

Double-negative (DN) B Cells: an Under-Recognized Effector Memory B Cell Subset in Autoimmunity

CD3+CD4-CD8- (Double-Negative) T Cells in Inflammation, Immune Disorders and Cancer.

Double-negative T cells: a promising avenue of adoptive cell therapy in transplant oncology

Depiction of Immune Heterogeneity of Peripheral Blood from Patients with Type II Diabetic Nephropathy Based on Mass Cytometry

Transcriptome landscape of double negative T cells by single-cell RNA sequencing

Subset of DN Memory B Cells Expressing Low Levels of Inhibitory Receptor BTLA Is Enriched in SLE Patients

Double Negative B Cell is Associated with Renal Impairment in Systemic Lupus Erythematosus and Acts As a Marker for Nephritis Remission.

Legend or Truth: Mature CD4+CD8+ Double-Positive T Cells in the Periphery in Health and Disease

Peripheral memory B cells in multiple sclerosis vs. double negative B cells in neuromyelitis optica spectrum disorder: disease driving B cell subsets during CNS inflammation

Ex Vivo Converted Double Negative T Cells Suppress Activated B Cells

Helper T cells down-regulate CD4 expression upon chronic stimulation giving rise to double-negative T cells

Advances in the research of B1-cell and its relationship with diseases

Double-negative T cells with a distinct transcriptomic profile are abundant in the peripheral blood of patients with breast cancer

NKG2D Enhances Double-Negative T Cell Regulation of B Cells

Impaired CD27+IgD+ B Cells with Altered Gene Signature in Rheumatoid Arthritis

Two distinct durable human class-switched memory B cell populations are induced by vaccination and infection

Β2 Integrin Deficiency Yields Unconventional Double‐negative T Cells Distinct from Mature Classical Natural Killer T Cells in Mice

Double-Negative T (DNT) Cells in Patients with Systemic Lupus Erythematosus

Double-negative T regulatory cells can develop outside the thymus and do not mature from CD8+ T cell precursors

Metabolic requirements of human pro-inflammatory B cells in aging and obesity

Autoantibodies elicited with SARS-CoV-2 infection are linked to alterations in double negative B cells